- Conditions
- Breast Cancer
- Interventions
- Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Biological · Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Hickory, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 138
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Fertility, Contraception
- Interventions
- Leuprolide acetate, Estrogen and Progesterone Replacement, Progestin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
- Interventions
- Talimogene laherparepvec, Paclitaxel
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Leiomyoma
- Interventions
- CDB-2914
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 33 Years to 50 Years · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Refractory Endometrial Serous Adenocarcinoma, Refractory Endometrial Undifferentiated Carcinoma
- Interventions
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment, Questionnaire Administration, Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive), Progesterone Receptor Positive ( PGR Positive; PR Positive)
- Drug · Other · Diagnostic Test
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Abington, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Anorexia Nervosa
- Interventions
- RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 22 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Adenocarcinoma
- Interventions
- Standard of Care Schedule Variation: SABR, Breast-conserving Surgery
- Other · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Estriol, Placebo, Copaxone
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
- Conditions
- Turner Syndrome, Hypogonadism, Premature Ovarian Failure
- Interventions
- 17 B estradiol orally, 17 B estradiol
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 13 Years to 20 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- cisplatin, bevacizumab, doxorubicin, cyclophosphamide, paclitaxel
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Single nucleotide polymorphism (SNP), high performance liquid chromatography, measurements by DXA, questionnaire administration
- Genetic · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
- Conditions
- Breast Cancer
- Interventions
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
- Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Omaha, Nebraska
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Interventions
- Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis, Gene Expression Analysis, Systemic Chemotherapy, Tamoxifen Citrate, Aromatase Inhibition Therapy
- Procedure · Other · Genetic + 1 more
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Charlotte, North Carolina • Greensboro, North Carolina + 3 more
- Conditions
- Breast Neoplasms
- Interventions
- Dexamethasone, Trabectedin
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 21
- States / cities
- Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more
- Conditions
- Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
- Interventions
- CDX-011, Capecitabine
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 57 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive, Postmenopausal, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Imatinib Mesylate, Letrozole
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- microarray analysis, polymerase chain reaction, protein expression analysis, diagnostic laboratory biomarker analysis, fluorescent antibody technique, immunohistochemistry staining method, immunologic technique
- Genetic · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Female only
- Enrollment
- 957 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Lapatinib, Letrozole, Trastuzumab
- Drug
- Lead sponsor
- Baylor Breast Care Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Indianapolis, Indiana + 5 more
- Conditions
- Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)
- Interventions
- transdermal 17β-E2 with cyclic progestin, oral 17β-E2 with cyclic progestin, transdermal EE+LNG
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 14 Years to 30 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Charlottesville, Virginia
- Conditions
- Infertility, Female
- Interventions
- FET Protocol
- Other
- Lead sponsor
- Reproductive Medicine Associates of New Jersey
- Other
- Eligibility
- 18 Years to 53 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Basking Ridge, New Jersey • Marlton, New Jersey
- Conditions
- HIV Prevention
- Interventions
- Estrogen, Estrogen plus Progesterone
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Healthy Volunteers
- Interventions
- Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1994 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Pain
- Interventions
- acupuncture therapy, sham acupuncture
- Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 47
- States / cities
- Antioch, California • Fremont, California • Los Angeles, California + 36 more
- Conditions
- Covid19
- Interventions
- Placebo injection and placebo pill, Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule
- Other · Drug
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana